TY - JOUR
T1 - Long-term complications in youth-onset type 2 diabetes
AU - Bjornstad, Petter
AU - Drews, Kimberly L.
AU - Caprio, Sonia
AU - Gubitosi-Klug, Rose
AU - Nathan, David M.
AU - Tesfaldet, Bereket
AU - Tryggestad, Jeanie
AU - White, Neil H.
AU - Zeitler, Philip
N1 - Funding Information:
Supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (U01DK61212, U01DK61230, U01DK61239, U01DK61242, and U01DK61254), the National Center for Research Resources (NCRR) General Clinical Research Centers Program (M01RR00036 [to the Washington University School of Medicine], M01RR0004345 [to Children’s Hospital Los Angeles], M01RR00069 [to the University of Colorado Denver], M01RR00084 [to Children’s Hospital of Pittsburgh], M01RR01066 [to Massachusetts General Hospital], M01RR00125 [to Yale University], and M01RR14467 [to the University of Oklahoma Health Sciences Center]), and the NCRR Clinical and Translational Science Awards program (UL1RR024134 [to Children’s Hospital of Philadelphia], UL1RR024139 [to Yale University], UL1RR024153 [to Children’s Hospital of Pittsburgh], UL1RR024989 [to Case Western Reserve University], UL1RR024992 [to Washington University in St. Louis], UL1RR025758 [to Massachusetts General Hospital], and UL1RR025780 [to the University of Colorado Denver]).
Publisher Copyright:
© 2021 Massachussetts Medical Society. All rights reserved.
PY - 2021/7/29
Y1 - 2021/7/29
N2 - BACKGROUND The prevalence of type 2 diabetes in youth is increasing, but little is known regarding the occurrence of related complications as these youths transition to adulthood. METHODS We previously conducted a multicenter clinical trial (from 2004 to 2011) to evaluate the effects of one of three treatments (metformin, metformin plus rosiglitazone, or metformin plus an intensive lifestyle intervention) on the time to loss of glycemic control in participants who had onset of type 2 diabetes in youth. After completion of the trial, participants were transitioned to metformin with or without insulin and were enrolled in an observational follow-up study (performed from 2011 to 2020), which was conducted in two phases; the results of this follow-up study are reported here. Assessments for diabetic kidney disease, hypertension, dyslipidemia, and nerve disease were performed annually, and assessments for retinal disease were performed twice. Complications related to diabetes identified outside the study were confirmed and adjudicated. RESULTS At the end of the second phase of the follow-up study (January 2020), the mean ( }SD) age of the 500 participants who were included in the analyses was 26.4 }2.8 years, and the mean time since the diagnosis of diabetes was 13.3 }1.8 years. The cumulative incidence of hypertension was 67.5%, the incidence of dyslipidemia was 51.6%, the incidence of diabetic kidney disease was 54.8%, and the incidence of nerve disease was 32.4%. The prevalence of retinal disease, including more advanced stages, was 13.7% in the period from 2010 to 2011 and 51.0% in the period from 2017 to 2018. At least one complication occurred in 60.1% of the participants, and at least two complications occurred in 28.4%. Risk factors for the development of complications included minority race or ethnic group, hyperglycemia, hypertension, and dyslipidemia. No adverse events were recorded during follow-up. CONCLUSIONS Among participants who had onset of type 2 diabetes in youth, the risk of complications, including microvascular complications, increased steadily over time and affected most participants by the time of young adulthood. Complications were more common among participants of minority race and ethnic group and among those with hyperglycemia, hypertension, and dyslipidemia. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; ClinicalTrials.gov numbers, NCT01364350 and NCT02310724.).
AB - BACKGROUND The prevalence of type 2 diabetes in youth is increasing, but little is known regarding the occurrence of related complications as these youths transition to adulthood. METHODS We previously conducted a multicenter clinical trial (from 2004 to 2011) to evaluate the effects of one of three treatments (metformin, metformin plus rosiglitazone, or metformin plus an intensive lifestyle intervention) on the time to loss of glycemic control in participants who had onset of type 2 diabetes in youth. After completion of the trial, participants were transitioned to metformin with or without insulin and were enrolled in an observational follow-up study (performed from 2011 to 2020), which was conducted in two phases; the results of this follow-up study are reported here. Assessments for diabetic kidney disease, hypertension, dyslipidemia, and nerve disease were performed annually, and assessments for retinal disease were performed twice. Complications related to diabetes identified outside the study were confirmed and adjudicated. RESULTS At the end of the second phase of the follow-up study (January 2020), the mean ( }SD) age of the 500 participants who were included in the analyses was 26.4 }2.8 years, and the mean time since the diagnosis of diabetes was 13.3 }1.8 years. The cumulative incidence of hypertension was 67.5%, the incidence of dyslipidemia was 51.6%, the incidence of diabetic kidney disease was 54.8%, and the incidence of nerve disease was 32.4%. The prevalence of retinal disease, including more advanced stages, was 13.7% in the period from 2010 to 2011 and 51.0% in the period from 2017 to 2018. At least one complication occurred in 60.1% of the participants, and at least two complications occurred in 28.4%. Risk factors for the development of complications included minority race or ethnic group, hyperglycemia, hypertension, and dyslipidemia. No adverse events were recorded during follow-up. CONCLUSIONS Among participants who had onset of type 2 diabetes in youth, the risk of complications, including microvascular complications, increased steadily over time and affected most participants by the time of young adulthood. Complications were more common among participants of minority race and ethnic group and among those with hyperglycemia, hypertension, and dyslipidemia. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; ClinicalTrials.gov numbers, NCT01364350 and NCT02310724.).
UR - http://www.scopus.com/inward/record.url?scp=85111579019&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa2100165
DO - 10.1056/NEJMoa2100165
M3 - Article
C2 - 34320286
AN - SCOPUS:85111579019
SN - 0028-4793
VL - 385
SP - 416
EP - 426
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 5
ER -